Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer-Reference-Cited by-同舟云学术

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer

Published:2018-04-11 Issue:436 Volume:10 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Tanyi Janos L.¹^ORCID,Bobisse Sara²,Ophir Eran²,Tuyaerts Sandra²^ORCID,Roberti Annalisa¹^ORCID,Genolet Raphael²^ORCID,Baumgartner Petra²,Stevenson Brian J.³,Iseli Christian³^ORCID,Dangaj Denarda²,Czerniecki Brian⁴^ORCID,Semilietof Aikaterini²^ORCID,Racle Julien²³^ORCID,Michel Alexandra²,Xenarios Ioannis³^ORCID,Chiang Cheryl¹^ORCID,Monos Dimitri S.⁵,Torigian Drew A.⁶,Nisenbaum Harvey L.⁶^ORCID,Michielin Olivier²³,June Carl H.⁷^ORCID,Levine Bruce L.⁷^ORCID,Powell Daniel J.¹^ORCID,Gfeller David²³^ORCID,Mick Rosemarie⁸,Dafni Urania⁹^ORCID,Zoete Vincent²³,Harari Alexandre²,Coukos George¹²^ORCID,Kandalaft Lana E.¹²^ORCID

Affiliation:

1. Ovarian Cancer Research Center, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

2. Department of Oncology, Lausanne University Hospital, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne CH-1066, Switzerland.

3. Swiss Institute of Bioinformatics, Lausanne CH-1015, Switzerland.

4. Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

5. Immunogenetics Laboratory, Department of Pathology and Laboratory Medicine, The Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA.

6. Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.

7. Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA 19104, USA.

8. Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

9. Laboratory of Biostatistics, School of Health Sciences, National and Kapodistrian, University of Athens, Athens, Greece.

Abstract

Personalized cancer vaccines induce antitumor T cells that correlate with clinical benefit in patients with ovarian cancer.

Funder

NIH Office of the Director

NIH

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference66 articles.

1. Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: A review of the literature

2. Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial

3. First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer

4. Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides

5. Clinical trials of HER-2/neu-specific vaccines;Murray J. L.;Semin. Oncol.,2000

Cited by 303 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy for Ovarian Cancer: Disappointing or Promising?;Molecular Pharmaceutics;2024-01-17

2. Engineering Challenges and Opportunities in Autologous Cellular Cancer Immunotherapy;The Journal of Immunology;2024-01-15

3. Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice;Journal of Translational Medicine;2024-01-03

4. Recent advances in personalized cancer immunotherapy with immune checkpoint inhibitors, T cells and vaccines;Personalized Medicine;2024-01

5. Nanoparticle-based immunoengineering strategies for enhancing cancer immunotherapy;Journal of Controlled Release;2024-01